The company has developed activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, bronchiectasis, and cystic fibrosis.

This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels. Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of future exacerbations over the subsequent 12 months.

In addition to measuring biomarkers of respiratory inflammation, ProAxsis continues to pursue other key areas including but not limited to, bone health and COVID anti-bodies (in conjunction with global respiratory leader, AstraZeneca).

Additionally, ProAxsis offers clinical support through in-house sample analysis at its purpose-built laboratory facility in Belfast. These facilities are currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

Founded in August 2013 by Professor Brian Walker and Dr Lorraine Martin, ProAxsis has won numerous awards for entrepreneurialism (2014) and innovative business of the year (2018) and continues to push the boundaries of diagnostic key targets in respiratory and other aligned key areas of population health.

Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

ProAxsis is a fully owned subsidiary of Netscientific plc, the international life sciences and sustainability technology investment and commercialisation Group.